Johnson & Johnson Announces MoU with K Hospital to Elevate Cancer Care in Vietnam

This strategic collaboration focuses on strengthening diagnostic and treatment capabilities, aligning clinical practice, and building professional leadership to improve the standard of care in lung, prostate and hematology cancers..

Johnson & Johnson (Vietnam) Co., Ltd. (“Johnson & Johnson Vietnam”) has signed a Memorandum of Understanding (MoU) with K Hospital, marking the next phase of the company’s long-term commitment to strengthening oncology care in Vietnam. This strategic collaboration will deliver hospital-based program, including scientific forums, targeted training, and practice‑alignment activities, designed to strengthen diagnostic and treatment capabilities to support early detection, evidence‑based decisions and consistent care pathways across priority tumor areas.

Cancer remains a growing health challenge in Vietnam

Cancer continues to pose one of the most pressing public health challenges in Vietnam. According to GLOBOCAN, the country recorded an estimated 180,480 new cancer cases and 120,184 cancer-related deaths in 2022[1], highlighting the urgent need to accelerate earlier detection, strengthen multidisciplinary care models, and ensure that patients can access timely and consistent care.

Among the areas of priority, lung cancer, prostate cancer, and hematologic malignancies represent significant clinical challenges. In lung cancer, certain subgroups remain under-diagnosed due to limited awareness and testing, while access to targeted treatment options is still evolving. Prostate cancer incidence is also rising, yet access to advanced diagnostics and newer hormonal therapies remains limited. In hematology, improving diagnostic capabilities and standardizing care pathways are critical to enabling earlier intervention and better long-term outcomes for patients living with conditions such as multiple myeloma and leukemia. Addressing these challenges requires strategic collaboration across the healthcare ecosystem to support earlier diagnosis, enhance clinical decision-making, and expand opportunities for scientific exchange and research participation.

Strengthening oncology collaboration through strategic partnership

The MoU between Johnson & Johnson Vietnam and K Hospital will focus on advancing professional education, scientific collaboration, and practical knowledge exchange in oncology care. Johnson & Johnson Vietnam will collaborate and support a series of professional initiatives, including a scientific conference, a specialized research and publication workshop, continuing medical education (CME) programs, and multi-session scientific seminars covering lung, prostate, and hematologic cancers - along with training outreach to the Northern and North Central provinces. These activities are designed to strengthen clinical knowledge, promote multidisciplinary care, and support early evidence‑based decision‑making.

K Hospital will lead the implementation of the collaboration, hosting and delivering the programs, embedding standardized care pathways into routine clinical practice, and extending training to healthcare professionals across its regional networks. This MoU reflects Johnson & Johnson’s continued commitment to support the advancement of cancer care for patients by translating priorities identified by clinical experts into concrete, hospitalbased actions that strengthen oncology care delivery across the healthcare system.

Mr. Upendra Patkie, General Manager of Johnson & Johnson Innovative Medicine Vietnam, shared: “K Hospital plays a central role in transferring oncology knowledge, sharing guidelines, and ensuring that clinical practices are adapted and shared across Vietnam. By formalizing this collaboration, Johnson & Johnson is working at the heart of Vietnam’s cancer care system, where global evidence is translated into locally relevant care pathways. This MoU enables us to support earlier detection, consistent multidisciplinary decisions, and stronger alignment with evidence‑based treatments, so that progress in cancer care reaches patients more reliably.”